Consistently, the B2R antagonist icatibant (Firazyr, Takeda) has been approved for HAE and is in trials for several other indications, such as heart failure and SARS-CoV-2 infection, while various other B1R and B2R antagonists are also currently investigated in cancer [99]. This evidence concerns the gene BDKRB2 and hereditary angioedema.